BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30429594)

  • 1. The role of Prostate Imaging Reporting and Data System score in Gleason 3 + 3 active surveillance candidates enrollment: a diagnostic meta-analysis.
    Zhai L; Fan Y; Meng Y; Feng X; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):235-243. PubMed ID: 30429594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis.
    Guo R; Cai L; Fan Y; Jin J; Zhou L; Zhang K
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):221-8. PubMed ID: 25986915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of diagnostic performance between two prostate imaging reporting and data system versions: A systematic review.
    Li W; Xin C; Zhang L; Dong A; Xu H; Wu Y
    Eur J Radiol; 2019 May; 114():111-119. PubMed ID: 31005160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
    Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
    Yim JH; Kim CK; Kim JH
    J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
    Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
    Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.
    Hamoen EHJ; de Rooij M; Witjes JA; Barentsz JO; Rovers MM
    Eur Urol; 2015 Jun; 67(6):1112-1121. PubMed ID: 25466942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
    Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
    Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Epstein Criteria with Biopsy-Naïve Multiparametric Magnetic Resonance Imaging to Prevent Incorrect Assignment to Active Surveillance in the PI-RADS Version 2.0 Era.
    Fan Y; Zhai L; Meng Y; Chen Y; Sun S; Wang H; Hu S; Shen Q; Liu Y; Li D; Feng X; He Q; Wang X; Yu W; Jin J
    Ann Surg Oncol; 2018 Nov; 25(12):3510-3517. PubMed ID: 30225837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
    Woo S; Suh CH; Kim SY; Cho JY; Kim SH
    Eur Urol; 2017 Aug; 72(2):177-188. PubMed ID: 28196723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy.
    Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
    Urol Int; 2017; 99(2):177-185. PubMed ID: 28531902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
    Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
    Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
    Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
    Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
    Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
    Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 20. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.